Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 7Active not recruiting 5Completed 4Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 1Locally Advanced Rectal Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × peposertib × Clear all
NCT03724890 2025-04-10

Study of Avelumab-M3814 Combinations

EMD Serono

Phase 1 Completed
57 enrolled 56 charts
Tumor-Agnostic

Neoplasms

NCT02516813 2024-10-15

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

EMD Serono

Phase 1 Completed
52 enrolled 43 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03770689 2023-03-21

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

EMD Serono

Phase 1/2 Completed
19 enrolled 21 charts
Gastrointestinal

Locally Advanced Rectal Cancer

NCT02316197 2020-04-28

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
31 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡